NCT04585009View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

June 16, 2022

Study Completion Date

June 16, 2022

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK3923868

GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

DRUG

Matching placebo

Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.

DEVICE

Monodose RS01

Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY